EQ

NASDAQ open

Equillium

1.07 USD
▼-0.05-4.46%
盘后 1.34 0.00%
2026-11-20
市值
$87.26M
市盈率
—
EPS
-0.18
股息率
—
52 周区间
0.81 – 3.54
成交量
500.29K
Beta
2.04
目标价
8.56
52W 低 0.8152W 高 3.54
价格走势

公司简介

Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its n...

关联新闻